NO970624L - In vivo mutasjoner og polymorfismer i det 17q-koblete bryst-og ovariekreft mottagelighetsgener - Google Patents

In vivo mutasjoner og polymorfismer i det 17q-koblete bryst-og ovariekreft mottagelighetsgener

Info

Publication number
NO970624L
NO970624L NO970624A NO970624A NO970624L NO 970624 L NO970624 L NO 970624L NO 970624 A NO970624 A NO 970624A NO 970624 A NO970624 A NO 970624A NO 970624 L NO970624 L NO 970624L
Authority
NO
Norway
Prior art keywords
ovarian cancer
breast
mutations
human
gene
Prior art date
Application number
NO970624A
Other languages
English (en)
Norwegian (no)
Other versions
NO970624D0 (no
Inventor
Donna M Shattuck-Eidens
Jacques Simard
Mitsuru Emi
Yusuke Nakamura
Francine Durocher
Original Assignee
Myriad Genetics Inc
Rech Du Chul Centre
Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27569596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO970624(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/483,553 external-priority patent/US5709999A/en
Priority claimed from US08/480,784 external-priority patent/US5693473A/en
Application filed by Myriad Genetics Inc, Rech Du Chul Centre, Cancer Inst filed Critical Myriad Genetics Inc
Publication of NO970624D0 publication Critical patent/NO970624D0/no
Publication of NO970624L publication Critical patent/NO970624L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO970624A 1994-08-12 1997-02-11 In vivo mutasjoner og polymorfismer i det 17q-koblete bryst-og ovariekreft mottagelighetsgener NO970624L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US28922194A 1994-08-12 1994-08-12
US30026694A 1994-09-02 1994-09-02
US30810494A 1994-09-09 1994-09-09
US34882494A 1994-11-29 1994-11-29
US40930595A 1995-03-24 1995-03-24
US08/483,553 US5709999A (en) 1994-08-12 1995-06-07 Linked breast and ovarian cancer susceptibility gene
US08/480,784 US5693473A (en) 1994-08-12 1995-06-07 Linked breast and ovarian cancer susceptibility gene
PCT/US1995/010202 WO1996005306A2 (en) 1994-08-12 1995-08-11 IN VIVO MUTATIONS AND POLYMORPHISMS IN THE 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE

Publications (2)

Publication Number Publication Date
NO970624D0 NO970624D0 (no) 1997-02-11
NO970624L true NO970624L (no) 1997-04-14

Family

ID=27569596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970624A NO970624L (no) 1994-08-12 1997-02-11 In vivo mutasjoner og polymorfismer i det 17q-koblete bryst-og ovariekreft mottagelighetsgener

Country Status (16)

Country Link
EP (1) EP0705903B2 (de)
JP (1) JP2002503943A (de)
CN (1) CN1172502A (de)
AT (1) ATE201445T1 (de)
AU (1) AU686004B2 (de)
CA (1) CA2196797C (de)
DE (1) DE69521002T3 (de)
DK (1) DK0705903T3 (de)
ES (1) ES2158048T5 (de)
FI (1) FI970513A7 (de)
GR (1) GR3036322T3 (de)
MX (1) MX9701075A (de)
NO (1) NO970624L (de)
NZ (1) NZ291621A (de)
PT (1) PT705903E (de)
WO (1) WO1996005306A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
EP0804453A4 (de) * 1995-01-17 2004-08-11 Univ Vanderbilt Verfahren zum nachweis und zur behandlung von brustkrebs
US6951721B2 (en) 1996-02-12 2005-10-04 Gene Logic Inc. Method for determining the haplotype of a human BRCA1 gene
US6838256B2 (en) * 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US5654155A (en) * 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene
US5891857A (en) * 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
WO1998012327A2 (en) * 1996-09-20 1998-03-26 Board Of Regents, The University Of Texas System Compositions and methods comprising bard1 and other brca1 binding proteins
JP2001511011A (ja) 1997-01-21 2001-08-07 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 腫瘍壊死因子レセプター−１誘導性アポトーシスおよびｃｄ−９５誘導性アポトーシスの新規なインヒビターである、ｉ−ｆｌｉｃｅ
US5965377A (en) * 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
WO1998055650A1 (en) * 1997-06-04 1998-12-10 Rijksuniversiteit Te Leiden A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
CA2308766C (en) 1997-11-06 2007-03-20 Oklahoma Medical Research Foundation Diagnostic assay for cancer susceptibility
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DK1507556T3 (en) 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
WO2005053662A1 (en) 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
KR101138862B1 (ko) 2005-02-14 2012-05-14 삼성전자주식회사 단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법
KR101206028B1 (ko) * 2005-03-05 2012-11-28 삼성전자주식회사 유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
CA2652167A1 (en) 2006-05-31 2007-12-06 Philip Jones Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
EP2805945B1 (de) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amidsubstituierte Indazole als Poly-(ADP-Ribose)-Polymerase (PARP)-Hemmer
JP2010539149A (ja) 2007-09-14 2010-12-16 アストラゼネカ アクチボラグ フタラジノン誘導体
JP5593229B2 (ja) 2007-10-17 2014-09-17 クドス ファーマシューティカルズ リミテッド ４−［３−（４−シクロプロパンカルボニル−ピペラジン−１−カルボニル）−４−フルオロ−ベンジル］−２ｈ−フタラジン−１−オン
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2767537B1 (de) 2008-08-06 2017-04-12 Medivation Technologies, Inc. Dihydropyridophthalazinonhemmer der Poly(ADP-Ribose)Polymerase (PARP)
ES2598178T5 (es) 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
CN107254538A (zh) 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
UY32790A (es) 2009-07-15 2011-02-28 Astrazeneca Ab Compuesto de ftalazinona
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
CN104789664A (zh) * 2015-04-02 2015-07-22 安诺优达基因科技(北京)有限公司 用于乳腺癌易感基因BRCA1和BRCA2的Long-range PCR检测的引物组、方法及试剂盒
JP6786066B2 (ja) 2016-10-07 2020-11-18 富士通株式会社 家系図作成支援プログラム、家系図作成支援方法、及び家系図作成支援装置
CN112566666A (zh) 2018-05-14 2021-03-26 努瓦申生物公司 靶向抗癌核激素受体的化合物
CN109897852A (zh) * 2018-07-25 2019-06-18 广州普世利华科技有限公司 基于C2c2的肿瘤相关突变基因的gRNA、检测方法、检测试剂盒
JP2022532342A (ja) 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CN113388680B (zh) * 2020-03-14 2023-07-04 复旦大学附属妇产科医院 上皮性卵巢癌靶点ret及其在诊断和治疗中的作用
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
AU2021356762A1 (en) 2020-10-09 2023-05-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
TW202304928A (zh) 2021-03-23 2023-02-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2022271547A1 (en) 2021-06-21 2022-12-29 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
CN118414173A (zh) 2021-11-18 2024-07-30 阿斯利康(英国)有限公司 抗体-药物缀合物和parp1选择性抑制剂的组合
JP2025503465A (ja) 2021-12-21 2025-02-04 アストラゼネカ・アクチエボラーグ 脳腫瘍及び神経芽腫を処置する方法
EP4456899A1 (de) 2021-12-28 2024-11-06 AstraZeneca UK Limited Kombination aus einem antikörper-wirkstoff-konjugat und einem rasg12c-hemmer
US20250064967A1 (en) 2021-12-28 2025-02-27 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atr inhibitor
CA3255700A1 (en) 2022-03-16 2023-09-21 Astrazeneca Uk Limited A scoring method for an anti-trop2 antibody‑drug conjugate therapy
IL316016A (en) 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
IL316019A (en) 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
CN119212702A (zh) 2022-04-07 2024-12-27 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
AU2023290506A1 (en) 2022-06-15 2025-01-23 Astrazeneca Ab Combination therapy for treating cancer
TW202412859A (zh) 2022-07-28 2024-04-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及雙特異性檢查點抑制劑之組合
TW202440169A (zh) 2022-11-30 2024-10-16 日商第一三共股份有限公司 抗體-藥物結合物與dnmt抑制劑之組合
KR20250165438A (ko) 2023-03-31 2025-11-25 아스트라제네카 아베 Azd5305의 투여 레지먼
WO2025088496A1 (en) 2023-10-24 2025-05-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
TW202535479A (zh) 2023-12-05 2025-09-16 英商阿斯特捷利康英國股份有限公司 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
TW202545525A (zh) 2024-01-19 2025-12-01 瑞典商阿斯特捷利康公司 包含ａｚｄ５３０５之藥物組成物
WO2026052764A1 (en) 2024-09-06 2026-03-12 Astrazeneca Uk Limited A scoring method for an anti-trop2 antibody drug conjugate therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
AU8221191A (en) * 1990-06-27 1992-01-23 Princeton University Probes for detecting mutant p53
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1994000764A1 (en) * 1992-06-26 1994-01-06 THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES The met proto-oncogene and a method for predicting breast cancer progression
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
EP0804453A4 (de) * 1995-01-17 2004-08-11 Univ Vanderbilt Verfahren zum nachweis und zur behandlung von brustkrebs

Also Published As

Publication number Publication date
NZ291621A (en) 1998-09-24
AU3321295A (en) 1996-03-07
DE69521002T3 (de) 2010-02-25
FI970513A0 (fi) 1997-02-07
ATE201445T1 (de) 2001-06-15
NO970624D0 (no) 1997-02-11
PT705903E (pt) 2001-11-30
CN1172502A (zh) 1998-02-04
DE69521002D1 (de) 2001-06-28
WO1996005306A3 (en) 1996-03-14
ES2158048T5 (es) 2009-11-04
EP0705903B1 (de) 2001-05-23
DK0705903T3 (da) 2001-08-27
CA2196797C (en) 2000-10-10
EP0705903A1 (de) 1996-04-10
ES2158048T3 (es) 2001-09-01
DE69521002T2 (de) 2001-11-15
MX9701075A (es) 1998-03-31
GR3036322T3 (en) 2001-11-30
CA2196797A1 (en) 1996-02-22
FI970513A7 (fi) 1997-04-07
WO1996005306A2 (en) 1996-02-22
JP2002503943A (ja) 2002-02-05
AU686004B2 (en) 1998-01-29
EP0705903B2 (de) 2009-08-12

Similar Documents

Publication Publication Date Title
NO970624L (no) In vivo mutasjoner og polymorfismer i det 17q-koblete bryst-og ovariekreft mottagelighetsgener
NO970625L (no) 17q-koblete bryst- og ovariekreft mottagelighetsgener
NO982785L (no) Kromosom 13-koblet brystkreftmottagelighetsgen
Tavtigian et al. A candidate prostate cancer susceptibility gene at chromosome 17p
EP1260520A3 (de) Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
Truderung et al. Melanoma susceptibility: An update on genetic and epigenetic findings
EP0756488A4 (de) Tumor-suppressor-gen und verfahren zum nachweis von krebs
Alimirzaie et al. Mutations in known and novel cancer susceptibility genes in young patients with pancreatic cancer
Bijlsma et al. Misleading linkage results in an NF2 presymptomatic test owing to mosaicism.
Martin et al. Exclusion of PITX2 mutations as a major cause of CHARGE association
Wang et al. Braf mutations initiate the development of rat gliomas induced by postnatal exposure to N-Ethyl-N-nitrosourea
Wu et al. Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.
Wan et al. Two variants of the human hepatocellular carcinoma‐associated HCAP1 gene and their effect on the growth of the human liver cancer cell line Hep3B
Haytural et al. Identification of a novel BRCA2 and CHEK2 ACGC haplotype in Turkish patients affected with breast cancer
Venkateshwari et al. BRIP1/FANCJ mutation analysis in a family with history of male and female breast Cancer in India
Cannon‐Albright et al. A rare FGF5 candidate variant (rs112475347) for predisposition to nonsquamous, nonsmall‐cell lung cancer
Strange et al. PTCH polymorphism is associated with the rate of increase in basal cell carcinoma numbers during follow‐up: preliminary data on the influence of an exon 12‐exon 23 haplotype
Nilbert et al. Novel germline APC mutations in Swedish patients with familial adenomatous polyposis and Gardner syndrome
Tell-Marti et al. The p. R151c polymorphism in mc1r gene modifies the age of onset in spanish huntington’s disease patients
Feng et al. Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2‐related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families
Espinós et al. Ala397Asp mutation of myosin VIIA gene segregating in a Spanish family with type-Ib Usher syndrome
WO2001085911A3 (en) Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes
Bale et al. Cancer-associated genodermatoses and familial cancer syndromes with cutaneous manifestations
MX9701076A (es) Metodo para diagnosticar una predisposicion para cancer de pecho y ovario.
Lebhard The effects of SNP285 and SNP309 on the expression of MDM2 and p53 in breast cancer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application